查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523255

微生物组治疗市场报告：2030 年趋势、预测与竞争分析

Microbiome Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

微生物组治疗趋势和预测

预计到 2030 年，全球微生物组治疗市场将达到 11 亿美元，2024 年至 2030 年复合年增长率为 32.4%。该市场的主要驱动力是微生物组治疗研发中策略合作的数量不断增加以及目标疾病盛行率的快速上升。全球微生物组治疗市场的未来看起来充满希望，艰难梭菌、克隆氏症、发炎性肠道疾病和糖尿病市场都有机会。

按细分领域进行微生物组治疗

该研究包括按类型、应用和地区分類的全球微生物治疗的预测。

微生物组治疗市场洞察

Lucintel 预测，由于专注于发现 FMT 其他治疗用途的研究和开发不断增加，FMT 在预测期内将继续占据更大的份额。

在这个市场中，艰难梭菌预计将经历最高的成长。

由于该地区目标人口不断增长，北美在整个预测期内仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球微生物组治疗市场预计将达到 11 亿美元。

Q2.市场成长预测是多少：

A2. 2024年至2030年，全球微生物组治疗市场预计将以32.4%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动力是微生物组治疗研发中策略合作的增加以及目标疾病盛行率的快速增加。

Q4.市场的主要细分市场是：

A4. 微生物组治疗市场的未来充满希望，艰难梭菌、克隆氏症、发炎性肠道疾病和糖尿病市场充满机会。

Q5.市场的主要企业是：

A5. 微生物治疗领域的主要企业有：

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测，由于致力于发现 FMT 的其他治疗用途的研究和开发不断增加，FMT 在预测期内将继续成为一个更大的细分市场。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于该地区的目标人口不断增长，北美在整个预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球微生物组治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球微生物组治疗市场趋势（2018-2023）与预测（2024-2030）
  • 全球微生物组治疗市场：按类型
    • FMT
    • 微生物医学
  • 全球微生物组治疗市场：依应用分类
    • 艰难梭菌（C. difficile）
    • 克隆氏症
    • 发炎性肠道疾病
    • 糖尿病
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球微生物组治疗市场（按地区）
  • 北美微生物组治疗市场
  • 欧洲微生物组治疗市场
  • 亚太微生物组治疗市场
  • 其他地区微生物组治疗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
  • 全球微生物组治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球微生物组治疗市场的产能
    • 全球微生物组治疗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix
简介目录

Microbiome Therapeutic Trends and Forecast

The future of the global microbiome therapeutic market looks promising with opportunities in the c. difficile, crohn's disease, and inflammatory bowel disease, and diabetes markets. The global microbiome therapeutic market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 32.4% from 2024 to 2030. The major drivers for this market are rising number of strategic collaborations for microbiome therapeutics for R&D and surge in the prevalence of target disease.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Microbiome Therapeutic by Segment

The study includes a forecast for the global microbiome therapeutic by type, application, and region.

Microbiome Therapeutic Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • FMT
  • Microbiome Drug

Microbiome Therapeutic Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • C. Difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

Microbiome Therapeutic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Microbiome Therapeutic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies microbiome therapeutic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the microbiome therapeutic companies profiled in this report include-

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix

Microbiome Therapeutic Market Insights

Lucintel forecasts that FMT will remain larger segment over the forecast period due to rising R&D focusing on developments to discover other therapeutic applications of FMT.

Within this market, c. difficile is expected to witness the highest growth.

North America will remain the largest region over the forecast period due to growing target population in the region.

Features of the Global Microbiome Therapeutic Market

Market Size Estimates: Microbiome therapeutic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Microbiome therapeutic market size by type, application, and region in terms of value ($B).

Regional Analysis: Microbiome therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the microbiome therapeutic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the microbiome therapeutic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the microbiome therapeutic market size?

Answer: The global microbiome therapeutic market is expected to reach an estimated $1.1 billion by 2030.

Q2. What is the growth forecast for microbiome therapeutic market?

Answer: The global microbiome therapeutic market is expected to grow with a CAGR of 32.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the microbiome therapeutic market?

Answer: The major drivers for this market are rising number of strategic collaborations for microbiome therapeutics for R&D and surge in the prevalence of target disease.

Q4. What are the major segments for microbiome therapeutic market?

Answer: The future of the microbiome therapeutic market looks promising with opportunities in the c. difficile, crohn's disease, and inflammatory bowel disease, and diabetes markets.

Q5. Who are the key microbiome therapeutic market companies?

Answer: Some of the key microbiome therapeutic companies are as follows:

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix

Q6. Which microbiome therapeutic market segment will be the largest in future?

Answer: Lucintel forecasts that FMT will remain larger segment over the forecast period due to rising R&D focusing on developments to discover other therapeutic applications of FMT.

Q7. In microbiome therapeutic market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing target population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the microbiome therapeutic market by type (FMT and microbiome drug), application (c. difficile, crohn's disease, inflammatory bowel disease, diabetes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Microbiome Therapeutic Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Microbiome Therapeutic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Microbiome Therapeutic Market by Type
    • 3.3.1: FMT
    • 3.3.2: Microbiome Drug
  • 3.4: Global Microbiome Therapeutic Market by Application
    • 3.4.1: C. difficile
    • 3.4.2: Crohn's disease
    • 3.4.3: Inflammatory Bowel Disease
    • 3.4.4: Diabetes
    • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Microbiome Therapeutic Market by Region
  • 4.2: North American Microbiome Therapeutic Market
    • 4.2.1: North American Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.2.2: North American Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others
  • 4.3: European Microbiome Therapeutic Market
    • 4.3.1: European Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.3.2: European Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others
  • 4.4: APAC Microbiome Therapeutic Market
    • 4.4.1: APAC Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.4.2: APAC Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others
  • 4.5: ROW Microbiome Therapeutic Market
    • 4.5.1: ROW Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.5.2: ROW Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Microbiome Therapeutic Market by Type
    • 6.1.2: Growth Opportunities for the Global Microbiome Therapeutic Market by Application
    • 6.1.3: Growth Opportunities for the Global Microbiome Therapeutic Market by Region
  • 6.2: Emerging Trends in the Global Microbiome Therapeutic Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Microbiome Therapeutic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Microbiome Therapeutic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: OpenBiome
  • 7.2: Seres Therapeutics
  • 7.3: Locus Biosciences
  • 7.4: 4D Pharma
  • 7.5: Enterome
  • 7.6: Finch Therapeutics
  • 7.7: Intralytix
  • 7.8: Microbiotica
  • 7.9: Second Genome
  • 7.10: Rebiotix